Hosted on MSN3h
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPC
Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
Targeted Oncology3h
Adding 177Lu-PSMA-617 to Enzalutamide Improves Survival, QOL in mCRPC
The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...
Medscape10h
Talazoparib Combo Prolongs Survival in Metastatic Prostate Cancer
Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...
Targeted Oncology1d
Talazoparib Plus Enzalutamide Extends Survival in mCRPC
Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...
The American Journal of Managed Care8h
TALAPRO-2 Overall Survival Data Suggest New Standard of Care in mCRPC, Regardless of Genomic Status
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Cancer Therapy Advisor1d
Talazoparib Improves OS as First-Line Treatment in mCRPC
Adding talazoparib to first-line treatment with enzalutamide can improve overall survival in patients with mCRPC, phase 3 data suggest.
FierceBiotech3d
Pfizer's investigational candidate combo cuts prostate cancer progression by 49% in phase 1
After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...
EPIX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of ESSA Pharma Inc. to Contact the Firm Today!
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Shareholders that lost money on ESSA Pharma Inc.(EPIX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn ...
Business Wire18d
Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
According to the lawsuit, defendants, throughout the Class Period, failed to disclose to investors that: (1) masofaniten in combination with enzalutamide had no clear efficacy benefit over ...